US OptionsDetailed Quotes
OTLK240816P7500
- 1.00
- 0.000.00%
15min DelayClose Jul 23 15:58 ET
0.00High0.00Low
1.00Open1.00Pre Close0 Volume11 Open Interest7.50Strike Price0.00Turnover180.91%IV23.71%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry1.00Extrinsic Value100Contract SizeAmericanOptions Type-0.3038Delta0.0887Gamma8.52Leverage Ratio-0.0287Theta-0.0021Rho-2.59Eff Leverage0.0076Vega
Outlook Therapeutics Stock Discussion
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
Outlook Therapeutics has received European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma), an ophthalmic formulation for treating wet AMD. This makes it the first ophthalmic bevacizumab formulation approved for wet AMD in the EU. This authorization covers all 27 EU Member States and will extend to Icela...
In an era where medical advancements are pivotal to enhancing quality of life, a significant breakthrough has been made in the treatment of wet age-related macular degeneration (AMD), a leading cause of vision loss among the elderly. Outlook Therapeutics, Inc. has received a positive opinion from the European Union's Committee for Me...
No comment yet